In both CSU and RA, disease control scores positively correlated with QoL scores, meaning better disease control was associated with better QoL. Despite this correlation, 5.9% of CSU patients and 28% ...
Clinical Trials Arena on MSN
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy ...
Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc., a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its ...
Novel treatments like dupilumab, remibrutinib, and barzolvolimab show promise in treating chronic spontaneous urticaria (CSU), especially in patients resistant to standard therapies. Autoimmune CSU, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback